radiotelegraph, ship radiotelephone and applicable radiotelephone including the logging of distress and safety calls where applicable.

Federal Communications Commission.

**Marlene Dortch,**

*Secretary, Office of the Secretary.*

[FR Doc. 2019–19134 Filed 9–4–19; 8:45 am]

**BILLING CODE 6712–01–P**

## FEDERAL MARITIME COMMISSION

### Notice of Agreements Filed

The Commission hereby gives notice of the filing of the following agreement under the Shipping Act of 1984. Interested parties may submit comments on the agreements to the Secretary by email at *Secretary@fmc.gov,* or by mail, Federal Maritime Commission, Washington, DC 20573, within twelve days of the date this notice appears in the **Federal Register**. Copies of agreements are available through the Commission's website (*www.fmc.gov*) or by contacting the Office of Agreements at (202) 523–5793 or *tradeanalysis@fmc.gov.*

*Agreement No.:* 201319.

*Agreement Name:* ''K'' Line/Kyowa Shipping—Japan/Guam/Saipan Car Carrier Space Charter Agreement.

*Parties:* Kawasaki Kisen Kaisha, Ltd. and Kyowa Shipping Co., Ltd.

*Filing Party:* John Meade; ''K'' Line America, Inc.

*Synopsis:* The Agreement authorizes the parties to charter space on each other's Ro/Ro vessels and to agree on cooperative working arrangements in the trade between ports in Japan, Guam, and Saipan.

*Proposed Effective Date:* 8/23/2019.

*Location: https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/22434.*

*Agreement No.:* 012440–001.

*Agreement Name:* WW Ocean and NYK Space Charter Agreement.

*Parties:* Wallenius Wilhelmsen Ocean AS and Nippon Yusen Kaisha.

*Filing Party:* Wayne Rohde; Cozen O'Connor.

*Synopsis:* The amendment changes the name of the Wallenius Wilhelmsen entity that is a party to the Agreement, corrects its address, and restates the Agreement.

*Proposed Effective Date:* 8/26/2019.

*Location: https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/1914.*

*Agreement No.:* 011836–002.

*Agreement Name:* WW Ocean/K-Line Space Charter Agreement.

*Parties:* Wallenius Wilhelmsen Ocean AS and Kawasaki Kisen Kaisha, Ltd.

*Filing Party:* Wayne Rohde; Cozen O'Connor.

*Synopsis:* The amendment changes the name of the Wallenius Wilhelmsen entity that is party to the Agreement, corrects its address, deletes obsolete language, and restates the Agreement. The amendment also expands the geographic scope of the agreement to cover all U.S. trades.

*Proposed Effective Date:* 10/12/2019.

Location: *https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/564.*

Dated: August 30, 2019.

**Rachel E. Dickon,**

*Secretary.*

[FR Doc. 2019–19196 Filed 9–4–19; 8:45 am]

**BILLING CODE 6731–AA–P**

## FEDERAL RESERVE SYSTEM

### Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than September 19, 2019.

*A. Federal Reserve Bank of Atlanta* (Kathryn Haney, Assistant Vice President) 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments can also be sent electronically to *Applications.Comments@atl.frb.org:*

1. *The Wade Family Partnership, Ltd. (''Partnership''), Carrollton, Alabama; William Oliver Kirk, Jr., individually and as general partner of the Partnership, Carrollton, Alabama; Geraldon Campbell Wade, Tuscaloosa, Alabama; the Andrew C. Wade Non-GST Exempt Marital Trust, Andrew C. Wade GST Exempt Marital Trust, and Andrew C. Wade GST Exempt Family Trust (collectively, the ''Trusts''), each of Birmingham, Alabama; Argent Trust Company, as trustee of the Trusts; Carol Wade McKinzey, individually and as trustee of the Trusts, Aliceville, Alabama; Andrew Cox Wade Jr., individually and as trustee of the Trusts, Tuscaloosa, Alabama; Donna Wade Cornelius, individually and as trustee of the Trusts, Tuscaloosa, Alabama; Mary Wade Price, Wiggins, Mississippi; John Jeffery Campbell, Gordo, Alabama; Carole Lamb Campbell, Gordo, Alabama; William Pate Wade, Tuscaloosa, Alabama; Andrew Cox Wade, III, Tuscaloosa, Alabama; Mary Ashley Wade, Tuscaloosa, Alabama; Caroline McKinzey Wright, Tuscaloosa, Alabama; and Jeffrey Kirk Cornelius, Jr., Tuscaloosa, Alabama;* to retain voting shares of West Alabama Capital Corp. and thereby indirectly retain shares of West Alabama Bank & Trust, both of Reform, Alabama.

*B. Federal Reserve Bank of Kansas City* (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001:

1. *Ryan G. Tessendorf, Columbus, Nebraska; and Wendy K. Matthews, Bemidji, Minnesota;* as a group acting in concert, to acquire voting shares of Bellwood Community Holding Company and thereby indirectly acquire shares of Bank of the Valley, both of Bellwood, Nebraska.

Board of Governors of the Federal Reserve System, August 30, 2019.

**Yao-Chin Chao,**

*Assistant Secretary of the Board.*

[FR Doc. 2019–19160 Filed 9–4–19; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

**[60-Day–19–1156; Docket No. CDC–2019–0078]**

### Proposed Data Collection Submitted for Public Comment and Recommendations

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice with comment period.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on Performance Monitoring of Working

with Publicly Funded Health Centers to Reduce Teen Pregnancy among Youth from Vulnerable Populations (OMB Control No. 0920–1156, Exp. 01/30/2020). A Revision is requested to continue collecting data through the end of the funding period and to develop systematic approaches to referring youth at risk for a teen pregnancy to reproductive health care.

**DATES:** CDC must receive written comments on or before November 4, 2019.

**ADDRESSES:** You may submit comments, identified by Docket No. CDC–2019–0078 by any of the following methods:

- *Federal eRulemaking Portal: Regulations.gov.* Follow the instructions for submitting comments.
- *Mail:* Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS–D74, Atlanta, Georgia 30329.

*Instructions:* All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to *Regulations.gov.*

*Please note:* Submit all comments through the Federal eRulemaking portal (*regulations.gov*) or by U.S. mail to the address listed above.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS–D74, Atlanta, Georgia 30329; phone: 404–639–7570; Email: *omb@cdc.gov.*

**SUPPLEMENTARY INFORMATION:** Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below.

The OMB is particularly interested in comments that will help:

1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

2. Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

3. Enhance the quality, utility, and clarity of the information to be collected; and

4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.,* permitting electronic submissions of responses.

5. Assess information collection costs.

**Proposed Project**

Performance Monitoring of Working with Publicly Funded Health Centers to Reduce Teen Pregnancy among Youth from Vulnerable Populations—Revision—Division of Reproductive Health (DRH), Centers for Disease Control and Prevention (CDC).

*Background and Brief Description*

Although the 2017 US rate of 18.8 births per 1,000 female teens aged 15–19 years represents a continued decline, the United States has one of the highest teen birth rates of all Western industrialized countries. Access to reproductive health services and the most effective types of contraception has been shown to reduce the likelihood that teens become pregnant. Nevertheless, recent research and lessons learned through a previous teen pregnancy prevention project implemented through CDC in partnership with the Office of Adolescent Health (2010–2015; OMB No. 0920–0952, Exp. 12/31/2015), demonstrate that many health centers serving teens do not engage in youth-friendly best practices that may enhance access to care and to the most effective types of contraception. Furthermore, youth at highest risk of experiencing a teen pregnancy are often not connected to the reproductive health care that they need, even when they are part of a population that is known to be at high risk for a teen pregnancy. Significant racial, ethnic and geographic disparities in teen birth rates persist and continue to be a focus of public health efforts.

To address these challenges, CDC has provided funding to three organizations to strengthen partnerships and processes that improve reproductive health services for teens. These awardees are working with 25 publicly funded health centers to support implementation of evidence-based recommendations for health centers and providers to improve adolescent access to reproductive health services. In addition, awardees have worked with approximately 30 youth-serving organizations (YSO) to provide staff training and develop systematic approaches to identifying youth who are at risk for a teen pregnancy and referring those youth to reproductive health care services. Finally, awardees have developed communication campaigns that increase awareness of the partner health centers' services for teens. Activities are expected to result in changes to health center and YSO partners' policies, to staff practices, and to youth health care seeking and teen pregnancy prevention behaviors.

The best practices to improve adolescent access to reproductive health services included in this program are supported by evidence in the literature and recommended by major medical associations. Each of the components of the current project has been implemented as part of past teen pregnancy prevention efforts. Consistent with CDC's mission of using evidence to improve public health programs, conducting an evaluation of combined best practices, in concert with community-clinical linkage of youth to services to increase their access to reproductive health care, can provide further information to inform future teen pregnancy prevention efforts.

CDC has been collecting the information needed to assess these efforts under Performance Monitoring of Working with Publicly Funded Health Centers to Reduce Teen Pregnancy among Youth from Vulnerable Populations (OMB Control No. 0920–1156, Exp. 1/31/2020). CDC is using the information to determine the types of training and technical assistance that may be needed to monitor whether awardees meet objectives related to health center and YSO partners' policies and staff practices, to support a data-driven quality improvement process for adolescent sexual and reproductive health care services and referrals, and to assess whether the project model was effective in increasing the utilization of services by youth.

A Revision of the currently approved information collection is being requested through 9/30/2020 in order to continue data collection until the end of the project. Remaining information collection activities will include awardees, health center partner organizations, and providers at the health center partners; information collection during the extension period

will not include YSOs or youths being served by health centers, as significant changes are not expected to be found for YSOs in the final year and that the youth survey will not need to be conducted beyond late 2019. Participation in the organizational assessment activities is required for awardees and partner organizations. Participation in a survey of health center providers is voluntary. The total estimated burden hours for the extension period are 485 hours.

ESTIMATED ANNUALIZED BURDEN HOURS

| Type of respondents | Form name | Number of respondents | Number of responses per respondent | Average burden per response (in hours) | Total burden (in hours) |
|---|---|---|---|---|---|
| Private Sector | Health Center Organizational Assessment | 21 | 1 | 2 | 42 |
| | Quarterly Health Center Performance Reporting Tool. | 21 | 2 | 4 | 168 |
| | Annual Health Center Performance Measure Reporting Tool. | 21 | 1 | 6 | 126 |
| | Health Center Provider Survey | 84 | 1 | 20/60 | 28 |
| | Awardee Training and Technical Assistance Tool. | 3 | 8 | 2 | 48 |
| | Awardee Performance Measure Reporting Tool | 3 | 1 | 1 | 3 |
| State and Local Government. | Health Center Organizational Assessment | 4 | 1 | 2 | 8 |
| | Quarterly Health Center Performance Measure Reporting Tool. | 4 | 2 | 4 | 32 |
| | Annual Health Center Performance Measure Reporting Tool. | 4 | 1 | 6 | 24 |
| | Health Center Provider Survey | 16 | 1 | 20/60 | 6 |
| Total | | | | | 485 |

**Jeffrey M. Zirger,**

*Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention.*

[FR Doc. 2019–19083 Filed 9–4–19; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. FDA–2013–N–0662]**

## Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Applications for Food and Drug Administration Approval To Market a New Drug—Patent Submission and Listing Requirements

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Fax written comments on the collection of information by October 7, 2019.

**ADDRESSES:** To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202–395–7285, or emailed to *oira_submission@omb.eop.gov.* All comments should be identified with the OMB control number 0910–0513. Also include the FDA docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–5733, *PRAStaff@fda.hhs.gov.*

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

### Applications for Food and Drug Administration Approval To Market a New Drug: Patent Submission and Listing Requirements

*OMB Control Number 0910–0513—Extension*

Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(c)(1)) requires all NDA applicants to file, as part of the NDA, the patent number and the expiration date of any patent that claims the drug for which the applicant submitted the application or that claims a method of using such drug and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner engaged in the manufacture, use, or sale of the drug. Section 505(c)(2) of the FD&C Act imposes a similar patent submission obligation on holders of approved NDAs when the NDA holder could not have submitted the patent information with its application. After approval of an NDA, under section 505(b)(1) of the FD&C Act, FDA publishes the patent information in the list entitled ''Approved Drug Products with Therapeutic Equivalence Evaluations'' (the Orange Book). When the patent information is submitted after NDA approval, section 505(c)(2) of the FD&C Act directs FDA to publish the patent information upon its submission.

FDA regulations in §§ 314.50(h) (21 CFR 314.50(h)) and 314.53 (21 CFR 314.53) clarify the types of patent information that must and must not be submitted to FDA as part of an NDA, an amendment, or a supplement to an NDA, and also require persons submitting an NDA, an amendment, or a supplement to make a detailed patent declaration on Form FDA 3542a, or when submitting information on a patent after approval of the NDA or supplement, to make a detailed patent declaration using Form FDA 3542.